Recently Featured

Novartis’ Rhapsido Shows Promise in Phase 2 Food Allergy Data

March 6, 2026
Novartis has presented encouraging preliminary results from a Phase 2 study of Rhapsido, a drug recently approved for treating hives, as it seeks to expand its application into the food allergy market. The study demonstrated that all three doses of Rhapsido led to significant improvements in patient outcomes, indicating its potential effectiveness in managing food…

Merck seeks expanded Welireg label with promising combo data from Keytruda and Lenvima

March 5, 2026
Merck is pursuing regulatory approval for two new combination therapies involving its drug Welireg for the treatment of kidney cancer, despite the absence of definitive data demonstrating an extension of patient survival. This strategic move follows the recent presentation of clinical results that indicate potential efficacy when Welireg is paired with established therapies like Keytruda…

Henrietta Lacks’ estate settles with Novartis over the ‘stolen cells’ that advanced science

March 5, 2026
Novartis has settled a lawsuit brought by the estate of Henrietta Lacks, which claimed that the pharmaceutical company unjustly profited from her cells taken without consent in 1951. These cells, known as HeLa cells, have been instrumental in numerous medical breakthroughs, including the development of the polio vaccine and advancements in cancer research. The settlement,…

Eli Lilly and Novo Nordisk Release Key GLP-1 Data Amid Leadership Changes

March 5, 2026
This week, Eli Lilly and Novo Nordisk unveiled significant data regarding their GLP-1 receptor agonists, which are pivotal in the treatment of obesity and diabetes. The results are expected to influence market dynamics and competitive positioning within the biopharmaceutical sector, as both companies aim to solidify their leadership in this lucrative space. Contextually, the advancements…

Ongoing Cases